Xencor. has filed a patent for novel GPC3 binding domains and antibodies for treating GPC3-associated cancers. The patent includes methods for using these antibodies. GlobalData’s report on Xencor gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Novel antibodies for treating gpc3-associated cancers
The patent application (Publication Number: US20240034815A1) describes a composition comprising a GPC3 antigen binding domain (ABD) with specific amino acid sequences for the variable heavy domain (VH) and variable light domain (VL). The composition includes various combinations of amino acid sequences for the VH and VL domains, providing a detailed framework for creating antibodies targeting the GPC3 antigen. Additionally, the patent application outlines a heterodimeric antibody structure consisting of two monomers, each with distinct variable heavy and light domains forming the GPC3 ABD. This structure allows for the creation of antibodies with specific binding capabilities to the GPC3 antigen, potentially enhancing their efficacy in targeted therapy.
Furthermore, the patent application includes a nucleic acid composition and an expression vector composition for encoding and expressing the variable heavy and light domains described in the previous claims. By providing a method for creating the anti-GPC3 ABD through culturing host cells containing the expression vectors, the patent application offers a comprehensive approach to producing these specialized antibodies. This method could have significant implications in the development of novel treatments for conditions where targeting the GPC3 antigen is crucial, potentially opening up new avenues for precision medicine and targeted therapy approaches.
To know more about GlobalData’s detailed insights on Xencor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
